Research programme: siRNA CNS disorder therapeutics - Quark Pharmaceuticals

Drug Profile

Research programme: siRNA CNS disorder therapeutics - Quark Pharmaceuticals

Latest Information Update: 23 Nov 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Quark Pharmaceuticals
  • Class Small interfering RNA
  • Mechanism of Action RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Research Neuropathic pain
  • Discontinued Neurodegenerative disorders; Spinal cord injuries

Most Recent Events

  • 22 Nov 2016 Discontinued - Preclinical for Neurodegenerative disorders and Spinal-cord-injuries in USA (unspecified route) (Quark Pharmaceuticals pipeline, November 2016)
  • 09 Nov 2016 Early research in Neuropathic pain (allodynia) in USA (Quark Pharmaceuticals pipeline, November 2016)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Neurodegenerative-disorders in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top